iRadimed Corporation's stock soared 8.95% during Tuesday's intraday trading session following the release of its fourth quarter and full-year 2025 financial results.

The medical device maker reported record Q4 revenue of $22.7 million, representing a 17% year-over-year increase and beating analyst estimates of $21.6 million. Adjusted earnings per share for the quarter came in at $0.54, surpassing the $0.48 consensus estimate and marking a 23% increase from the same period last year.

Investors responded positively to the company's announcement of an 18% increase in its quarterly cash dividend to $0.20 per share, as well as optimistic 2026 financial guidance projecting revenue between $91 million and $96 million and adjusted EPS between $2.06 and $2.21, both ranges aligning with or exceeding current analyst expectations.